Skip to content

A Clinical Study To Evaluate The Effectiveness Of Rasasindura In The Management Of Benign Prostatic Hyperplasia / Vatashteela

A Randomised Controlled Trial To Evaluate The Efficacy Of Rasasindura In The Management Of Vatashteela W.S.R To Benign Prostatic Hyperplasia - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106545
Enrollment
40
Registered
2026-03-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

None listed

Sponsors

Dr Ayisha Muskan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects who are presented with the symptoms of Benign prostatic hyperplasia and confirmed by digital rectal examination and ultrasound (Abdomen and pelvis) Male Patients in the age group of 50-70 years

Exclusion criteria

Exclusion criteria: Patients with other causes of the lower urinary tract symptoms like Neurogenic bladder Urethral stricture Carcinoma of the prostate PSA more than 30 mmol Subjects with uncontrolled diabetes mellitus and hypertension Acute or chronic retention of urine Subjects with Acute or chronic renal failure and Cardiac conditions

Design outcomes

Primary

MeasureTime frame
Change in International Prostate Symptom Score (IPSS) in patients with Benign Prostatic Hyperplasia before and after treatment. Reduction in Lower Urinary Tract Symptoms (LUTS) such as frequency, urgency, hesitancy, weak stream and nocturiaTimepoint: treatment given for 30 days follow-up done for 60 days

Secondary

MeasureTime frame
change in Post-void residual urine volume (PVR) measured by ultrasound.Timepoint: 3 months

Countries

India

Contacts

Public ContactDr Pawan B Lalsange

Dr.N.A.MAGADUM AYURVEDIC MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTER, ANKALI-591213

ambiciouspawan@gmail.com8748035055

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026